Silence Therapeutics Plc American Depository Share - SLN STOCK NEWS

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in two virtual investor conferences in September 2021. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, featuring a fireside chat at 11:45am EDT, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand starting at 7:00am EDT. Interested parties can access the webcasts through the Investors section of Silence's website, where archived replays will also be available.

Silence Therapeutics reported strong execution in its half-year results for 2021, achieving full enrollment for four cohorts of the APOLLO study on SLN360, which targets high lipoprotein(a) levels. The company raised £30.8 million from a successful private placement and increased its cash position to £81.2 million. Positive clinical data from the SLN124 study also supports ongoing programs. However, R&D and administrative expenses rose significantly compared to 2020, reflecting investment in personnel and clinical trials. Upcoming data from the APOLLO study is anticipated in Q1 2022.

Silence Therapeutics plc (AIM: SLN, Nasdaq: SLN) announces its financial and business results for the half-year period ending June 30, 2021, set for release on August 12, 2021, at 8:00 a.m. EDT. The company, specializing in innovative siRNA therapeutics, will provide an update via a conference call accessible through their website. Key products include SLN360 for cardiovascular risk and SLN124 for iron-loading anemia. Silence has research collaborations with major firms including AstraZeneca.

Silence Therapeutics has received the remaining $40 million from AstraZeneca, part of an $80 million investment for their ongoing siRNA collaboration aimed at treating cardiovascular, renal, metabolic, and respiratory diseases. This funding boosts Silence's proforma cash balance to £97.5 million at the end of 2020. The collaboration focuses on leveraging Silence's mRNAi GOLD™ platform to develop therapeutics for five targets within three years. AstraZeneca will pay additional milestone and royalty fees as development progresses.

Silence Therapeutics announced positive topline data from the GEMINI Phase 1 study of SLN124 in healthy volunteers. The siRNA targeting TMPRSS6 demonstrated safety, leading to a significant reduction in plasma iron levels and an approximate four-fold increase in hepcidin. Initial results showed no serious adverse events across multiple dose levels, indicating a good safety profile. This study supports ongoing research into SLN124 for treating thalassemia and myelodysplastic syndrome (MDS). Further clinical data from the GEMINI II study is anticipated later this year.

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 8:35 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Silence Therapeutics focuses on siRNA therapeutics for diseases with unmet medical needs, including cardiovascular risk and iron-loading anemias, leveraging its proprietary mRNAi GOLD™ platform. The company collaborates with AstraZeneca and others to further its research.

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) has launched an online game, Blood Run Beta, to raise awareness for thalassemia ahead of International Thalassemia Day on May 8, 2021. The game aims to educate players about thalassemia's impact, particularly fatigue, and encourages sharing scores on social media using #BloodRunBeta. Silence is also partnering with the Thalassaemia International Federation to support activities for the event, with this year's theme focusing on health inequalities in the thalassemia community. The initiative aims to enhance public understanding of this rare disorder.

Silence Therapeutics has achieved a significant milestone in its RNAi collaboration with Mallinckrodt, triggering a $2 million payment related to the SLN500 C3 targeting program. This payment highlights the ongoing success of their partnership focused on complement-mediated diseases.

Silence is progressing with Investigational New Drug (IND) enabling studies for SLN501 within this collaboration. The agreement includes a potential for $2 billion in total milestone payments and tiered royalties on net sales, reflecting a financially beneficial arrangement for Silence Therapeutics.

Silence Therapeutics plc (AIM:SLN, Nasdaq:SLN) has released a new review in Cardiovascular Research, focusing on RNA therapeutics for preventing cardiovascular disease linked to high lipoprotein(a) (Lp(a)) levels, a condition affecting around 20% of the global population. The review emphasizes RNA interference (RNAi) therapies, especially the lead candidate SLN360, which aims to lower Lp(a) levels significantly. Promising pre-clinical results indicate over 90% reduction in Lp(a) with a strong safety profile. Data from the ongoing APOLLO Phase 1 trial is expected in late 2021.